teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 48

vida: extract claims from 2025-12-16-icer-obesity-final-report-glp1-cost-effective-access
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details

Browse source 
- Source: inbox/queue/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents 2026-04-26 04:21:41 +00:00
parent fe1ab793ba
commit 7e06d3c3f4
2 changed files with 11 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

7
domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md
View file

@ -67,3 +67,10 @@ ITIF's 74 million eligible obesity treatment population figure provides the deno
**Source:** WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025 **Source:** WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025
WHO explicitly states that current global access and affordability for GLP-1s are 'far below population needs' and that GLP-1s 'should be incorporated into universal health coverage and primary care benefit packages' but acknowledges this is not yet reality anywhere in the developing world. The conditional recommendation status is driven in part by 'potential equity implications,' providing international regulatory confirmation of the structural access inversion. WHO explicitly states that current global access and affordability for GLP-1s are 'far below population needs' and that GLP-1s 'should be incorporated into universal health coverage and primary care benefit packages' but acknowledges this is not yet reality anywhere in the developing world. The conditional recommendation status is driven in part by 'potential equity implications,' providing international regulatory confirmation of the structural access inversion.
## Supporting Evidence
**Source:** ICER Final Evidence Report, December 2025
ICER report documents the access inversion at policy level: California Medi-Cal (serving lowest-income population) eliminated coverage January 2026 despite 14-0 clinical evidence. Medicare coverage restricted to cardiovascular risk indication, excluding pure obesity. National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' highlighting the structural tension between budget sustainability and individual access. The 14-0 clinical verdict combined with simultaneous coverage elimination is the clearest expression of structural misalignment.

5
inbox/queue/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md → inbox/archive/health/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md
View file

@ -7,9 +7,12 @@ date: 2025-12-16
domain: health domain: health
secondary_domains: [] secondary_domains: []
format: policy-report format: policy-report
status: unprocessed status: processed
processed_by: vida
processed_date: 2026-04-26
priority: high priority: high
tags: [glp-1, ICER, cost-effectiveness, obesity, coverage, affordability, Medicaid, Medicare, semaglutide, tirzepatide, budget-impact] tags: [glp-1, ICER, cost-effectiveness, obesity, coverage, affordability, Medicaid, Medicare, semaglutide, tirzepatide, budget-impact]
extraction_model: "anthropic/claude-sonnet-4.5"
--- ---
## Content ## Content